Category: Intellectual property
-
Genzyme Licensing Gene Therapies from Biotech Start-Up
11 February 2015. Voyager Therapeutics, a designer of gene therapies for central nervous system diseases, is licensing some of its treatments now in development to Genzyme Corp., a biotechnology subsidiary of the drug maker Sanofi. The deal is expected to bring the one year-old spin-off from four university research labs as much as $845 million.…
-
Biotech, Hospira to Partner on Biosimilar for Eye Disease
10 February 2015. Pfenex Inc., a biotechnology company in San Diego, is licensing its lead product to treat age-related macular degeneration to biologic therapy maker Hospira. The deal can bring Pfenex as much as $342 million, plus royalties on sales of products from the collaboration, over at least the next five years. Age-related macular degeneration is…
-
Neuropore, UCB Partner on Parkinson’s Drugs
16 January 2015. UCB, a biopharmaceutical company in Brussels, is licensing an experimental drug to treat Parkinson’s disease developed by Neuropore Therapies Inc., a biotechnology company in San Diego. The agreement gives UCB a worldwide license for the compound and is expected to pay Neuropore as much as $480 million. Parkinson’s disease occurs when the brain…
-
Roche Buys $1 Billion Stake in Cancer Genetics Company
12 January 2015. Pharmaceutical company Roche is acquiring a majority stake in Foundation Medicine, a company conducting personal genomic analyses for cancer patients. The investment, licensing, and collaboration deal is expected to bring Foundation Medicine, in Cambridge, Massachusetts more than $1 billion. Foundation Medicine — founded by scientists at Dana-Farber Cancer Institute, Harvard Medical School,…
-
Biotech Licenses Cell Research for Ebola Treatments
8 January 2015. H&P Labs, a biotechnology company in Montreal, is licensing research on cell proteins at a lab affliated with Harvard University to develop into treatments for Ebola. Financial details of the agreement were not disclosed. The current Ebola outbreak in Africa that began in March 2014 totals 20,747 cases resulting in 8,235 deaths,…
-
Novartis Licensing Biotechs’ Gene-Editing Technologies
7 January 2015. Pharmaceutical maker Novartis is licensing technologies from two biotechnology companies that enable the editing of human genomes to cure disease. Financial details of the agreements with Caribou Biosciences Inc. in Berkeley, California and Intellia Therapeutics in Cambridge, Massachusetts were not disclosed, but involve equity investments, initial payments and research support, and milestone…
-
Amgen, Kite Pharma Partner on Personal Cancer Immunotherapy
5 January 2014. The biotechnology companies Amgen and Kite Pharma are developing personalized cancer treatments harnessing the immune system in a deal combining Amgen’s targets with Kite Pharma’s cell therapies. The agreement is expected to bring up to $525 million in milestone payments plus sales royalties to each company, as well as an upfront payment…
-
Lilly, Biotech Partner on Fast-Acting Insulin Analog
19 December 2014. The pharmaceutical company Eli Lilly and Company and biotechnology company Adocia are collaborating on commercial development of Adocia’s fast-acting synthetic insulin product. Adocia, based in Lyon, France, can gain as much as $570 million in the deal, not counting royalties on future sales. Adocia develops enhanced formulations of protein-based therapies either on…
-
Janssen, Biotech Partner on Drug Delivery Technology
17 December 2014. Halozyme Therapeutics, a biotechnology company in San Diego, is licensing its drug delivery technology for under-the-skin injections to Janssen Biotech, one of the Janssen Pharmaceutical companies and a division of Johnson & Johnson. The deal is expected to bring Halozyme up to $581 million in initial and milestone payments. Halozyme develops synthetic…
-
Spin-Off Building Simplifed Signal Processing Connections
16 December 2014. An engineering lab at Columbia University in New York is spinning off a new company aiming to design simpler connections between analog and digital signals as systems get smaller and performance becomes more demanding. Seamless Devices Inc., founded by electrical engineering professor Peter Kinget and former graduate student Jayanth Kuppambatti, began in…